Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01390805

Enrollment

462

Registered

2011-07-11

Start date

2006-11-30

Completion date

2011-03-31

Last updated

2017-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genital Herpes

Brief summary

The purpose of this study is to collect and assess information on proper use of valaciclovir regarding safety and efficacy of long-term use in suppressive therapy for subjects with recurrent genital herpes.

Interventions

DRUGValaciclovir Hydrochloride.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subjects who started suppressive therapy for recurrent genital herpes for the first time

Exclusion criteria

* Subjects with a history of hypersensitivity to the ingredients of VALTREX or aciclovir

Design outcomes

Primary

Measure	Time frame
The number of adverse events in Japanese subjects with recurrent genital herpes treated with valaciclovir	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026